ESPE Abstracts

Introduction: Guidelines recommend starting growth hormone (rhGH) as soon as possible in pathological short stature to promote growth and normalize final height. Despite efficacy and safety of rhGH, about 70% of patients have poor adherence to treatment, with consequently reduced therapeutic response. Somatrogon, a weekly long-acting GH (LAGH), may improve the therapy compliance and efficacy, reducing the number of injections. Despite it has been demonstrated ...

Background: Hypophosphatemic rickets (HR) associated with elevated FGF23 plasma levels is a disorder characterized by renal phosphate wasting, leading to impaired bone mineralization. Conventional therapy, based on oral phosphate and calcitriol, has limited efficacy and tolerability. In 2018, burosumab, a monoclonal antibody against fibroblast growth factor 23 (FGF-23), was approved for the treatment of X-linked hypophosphatemia (XLH). However, data on burosum...